The Current Five-Year Business Plan (FY2026-FY2030)
2035 Vision
Trusted healthcare innovator transforming the lives of people through our science and technology
Key Initiatives in Our Current Five-Year Business Plan
Becoming a Global Top Five Oncology Company by 2035
- Innovation and advancement of care for patients with serious illness and bring the field of oncology one step closer to cure for patients worldwide
- Bringing novel treatment options focusing on personalized medicine to patients beyond the reach of conventional medicines
- By providing high-quality information to healthcare professionals and patients, deliver our medicine to more than 700K new eligible patients
Identifying the Next Breakthrough Generating Technologies (BGT) by 2030
BGT Platform: “Daiichi Sankyo’s proprietary technology” × “Research and development for multiple diseases”
- Generating multiple drug candidates through innovative technologies to transform standard of care
- Leveraging clinically validated technologies to build a high-probability portfolio
- Establishing end-to-end integrated capabilities from research to manufacturing to accelerate delivery of new medicines to patients
Enhancing Operational Excellence
- Optimizing the cost structure to enhance profit generation
- Establishing a Business Transformation function to drive company-wide Operational Excellence
- Centralizing all global commercialization activities
- Executing activities with greater speed and consistency worldwide
Initiatives toward “Be a Trusted Partner for Sustainable Society”
| Fostering Patient Centricity |
・Improving Patient Assistance Program
・Providing employees opportunities to understand patients’ perspectives and experiences
|
| Ethically contributing to medical communities |
・Deliver added value through continuous data and evidence generation
・Contribute as a partner in solving medical needs
|
| Acquiring and developing world-class-talent |
・Implementation of strategic talent management aligned with business priorities
・Implementation of next-generation executive development programs
|
| Further enhansing culture and work environment |
・Advanced management of standardized new HR frameworks globally
・Enhanced onboarding experience
|
| Maintaining high standard of compliance |
・Implementation of compliance training and monitoring
・Building a human rights due diligence framework
・Strengthen governance with business partners
|
| Maintaining low environmental burdenacross our value chain |
・Advancing net zero transition plan
・Ensure responsible chemical management with respect for local communities
|
 |
Creating value for diverse stakeholders, including patients and their families,
to achieve a sustainable society
|
Financial KPIs: FY2030
- Realize profit growth toward 2030 driven by DXd ADC sales expansion and operational excellence
- Identify new BGTs beyond DXd ADC to achieve 1.0 Tn JPY in operating profit in early 2030s
| Financial KPIs: FY2030 |
Revenue: > 3.0 Tn JPY
Operating profit: > 600.0 Bn JPY
EPS:> 260 JPY
Adjusted DOE:> 10.0% annually, with progressive dividends |
The last Business Plan (FY2021-FY2025) Recap: Target and the Results of FY2025